Also trades as: CINGW (NASDAQ) · $vol 0M
CING NASDAQ
Cingulate Inc.
1W: -1.4%
1M: -7.6%
3M: -10.2%
YTD: +8.7%
1Y: +13.6%
3Y: -97.1%
$4.76
+0.01 (+0.21%)
Weekly Expected Move ±4.7%
$4
$5
$5
$5
$5
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Moderate
50
Insider—
Congress—
ETF Holdings—
Key Statistics
Market Cap$64.1M
52W Range3.16-11.89
Volume52,068
Avg Volume407,141
Beta-0.89
Dividend—
Analyst Ratings
Company Info
CEOShane J. Schaffer
Employees14
SectorHealthcare
IndustryBiotechnology
IPO Date2021-12-08
Websitecingulate.com
1901 West 47th Place
Kansas City, KS 66205
US
Kansas City, KS 66205
US
913 942 2300
About Cingulate Inc.
Cingulate Inc. is a biopharmaceutical enterprise currently in its clinical development phase, dedicated to devising therapeutic options for attention-deficit/hyperactivity disorder (ADHD). Leading its pipeline for ADHD are two drug candidates: CTx-1301 (dexmethylphenidate), which is currently progressing through Phase 3 clinical trials, and CTx-1302 (dextroamphetamine). The company is also engaged in the advancement of CTx-2103, a candidate intended for the management of anxiety disorders. Founded in 2012, Cingulate Inc. maintains its corporate headquarters in Kansas City, Kansas.
Latest News
Cingulate Inc. Reports Second Quarter 2026 Financial Results and Provides Update on CTx-1301 CMC Progress Towards NDA Resubmission and Commercial Readiness
Cingulate added to Russell 3000E Index
12 Health Care Stocks Moving In Wednesday's Intraday Session
Cingulate Receives Complete Response Letter from FDA for CTx-1301
Cingulate Inc. Reports First Quarter 2026 Financial Results and Provides an Update of Commercial Readiness Efforts On Track for lead ADHD Asset CTx-1301
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Silva Raul R. | A-Award | 4,293 | $4.95 | 2026-09-30 |
| Hargroves Thomas Jef | A-Award | 20,000 | $4.43 | 2026-07-16 |
| Callahan Jennifer L. | A-Award | 40,200 | $4.43 | 2026-07-16 |
| Callahan Jennifer L. | A-Award | 19,800 | $4.43 | 2026-07-16 |
| Werth Peter J. | A-Award | 20,000 | $4.43 | 2026-07-16 |